HCWB hcwbiologics.com: Forward P/S Multiple
Fierce competition with biotech giants for patient access creates risks for HCW Biologics Inc. (HCWB). The forward P/S indicator reflects current market dynamics, where the metric is fixed at 0.30. Price stability is supported by a strong team of immunologists and generous stock options. Growth prospects are based on the implementation of new therapeutic platforms to attract significant investment capital.
Comprehensive metric breakdowns and analytics for hcwbiologics.com (HCWB)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt and solvency information:
- financial results and valuation multiples details:
HCWB - Company Net Income|Expected Profit HCW Biologics Inc.|HCWB - Market Cap to Earnings|Forward P/E Multiple HCW Biologics|HCWB - Price to Net Income Growth Ratio|EV/EBITDA Multiple HCW Biologics|HCWB - Operating income before deduction of amortization|Net earnings per share (EPS TTM) HCW Biologics|HCWB - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months hcwbiologics.com|HCWB - Expected net earnings per share growth this year|Expected earnings per share growth for next year HCW Biologics Inc.
- sales and revenue data:
Summary company analytics:HCW Biologics Inc HCWB
HCW Biologics Inc. (HCWB) resilience to market volatility is driven by the efficiency of cleanroom modernization and current capacity utilization for immunotherapy production. The company's modeled P/S ratio compares current market capitalization with expected sales volume, allowing investors to use this chart's price action to distinguish temporary crowd panic from a fundamental weakening of the asset, thereby ensuring an objective valuation of the business.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Forward Price to Sales ADMA (ADMA Corp)|PTGX: Forward P/S Multiple|Forward Price-to-Revenue Multiple immunovant.com|Forward Price-to-Revenue Multiple KNSA|Forward Price-to-Revenue Multiple Grifols SA (GRFS)|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com - Price-to-Projected Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|Price-to-Projected Revenue Ratio PGEN|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Forward P/S Multiple UPB (Upstream Bio Corp)|Projected Price to Revenue Zenas Corp|Immunome, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio gossamerbio.com GOSS|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna, Inc.|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|ANAB (anaptysbio.com) - Forward Price to Sales|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT - Price-to-Projected Revenue Ratio|JBIO (Aerovate Therapeutics Inc) - Market Cap to Projected Revenue|ACRS: Forward P/S Multiple|Forward Price-to-Revenue Multiple kyvernatx.com|Forward Price-to-Revenue Multiple TLSA|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VTYX|THTX (Theratechnologies, Inc) - Forward Price to Sales|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|ELDN - Forward Price-to-Revenue Multiple|AGEN: Forward Price-to-Revenue Multiple|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|ATYR (aTyr Pharmaceuticals) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Ikena Oncology, Inc. - Future Price to Revenue|Forward P/S Multiple STTK|EQ (equilliumbio.com) - Forward Price to Sales|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|Forward Price to Sales IFRX (InflaRx N.V.)|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adicet Bio, Inc.|CELU (Celularity Inc) - Forward P/S Multiple|Forward P/S Multiple INmune Bio Corporation|Forward Price-to-Revenue Multiple BRNS (Barinthus Biotherapeutics)|KZR (kezarlifesciences.com) - Forward Price to Sales|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio Akari Therapeutics PLC (AKTX)|ENLV - Price-to-Projected Revenue Ratio|Q32 Bio Inc. (QTTB) - Forward Price-to-Revenue Multiple|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple edesabiotech.com|Forward Price-to-Revenue Multiple IBIO|Forward P/S Multiple Carisma Tx|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|boltbio.com - Market Cap to Projected Revenue|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Market Cap to Future Revenue Ratio|Aditxt Corp - Forward P/S Multiple|Forward Price to Sales GRI (GRI Bio Inc)|XRTX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Vyome Therapeutics|Forward Price-to-Revenue Multiple REVB|Forward Price-to-Revenue Multiple indaptusrx.com (INDP)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Allakos Inc - Price-to-Projected Revenue Ratio|HOOKIPA - Forward P/S Multiple|Market Cap to Expected Sales Ratio IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Price-to-Projected Revenue Ratio THRD
